Milestone Scientific Inc.
MLSSMilestone Scientific Inc. in brief
Milestone Scientific Inc. is a listed company in the Medical Instruments industry, based in Livingston, New Jersey, USA. Its market value was $31 M on 14 October 2026, which makes it the 22,971st largest listed company in the world and the 4,034th largest in the USA on this site. In the year to December 2025 it had sales of $9 M and a net loss of $6 M. It employs about 15 people. Its largest product and service lines by sales in 2025 were Handpieces (80%) and Instruments (20%). By market, the largest shares of its 2025 sales came from USA (55%) and China (3%). Its shares trade under the symbol MLSS (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Milestone Scientific Inc.
Milestone Scientific Inc. was incorporated in the State of Delaware in August 1989. The Company develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures.
The Company’s core technology platform, Dynamic Pressure Sensing® Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the Company’s dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections.
From the company's annual report filed with the US SEC: read the report
Milestone Scientific Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1997
- ✎Renamed Milestone Scientific IncFormerly U S Opportunity Search Inc.
- 2015
- 🔔· approximateInitial public offering on NYSE
- 2021
- 💰Record revenue of $10 millionFY2021, the highest of the 8 years on record.
Events of Milestone Scientific Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,970 (Jan 2020) · #3,505 (Jan 2021) · #4,139 (Jan 2022) · #5,066 (Dec 2022) · #4,425 (Jul 2023) · #4,032 (Jan 2024) · #2,301 (Mar 2026) · #3,773 (Aug 2026) · #4,013 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 3.3×
- Price / book
- 11.0×
- Free cash flow yield
- -9.5%
- Net margin (TTM)
- -44.1%
- Operating margin
- -63.5%
- Return on equity
- -147.7%
- Liabilities / assets
- 63.9%
- Revenue growth
- +3.9%
- R&D / revenue
- 5.0%
- Revenue per employee
- $598 K
- Profit per employee
- $-381 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9M | +3.9% | $-6M | $-6M | -63.8% |
| Dec 2024 | $9M | -12.2% | $-7M | $-5M | -54.6% |
| Dec 2023 | $10M | +11.6% | $-7M | $-7M | -70.5% |
| Dec 2022 | $9M | -14.5% | $-9M | $-9M | -98.9% |
| Dec 2021 | $10M | +89.3% | $-7M | $-7M | -66.2% |
| Dec 2020 | $5M | -35.0% | $-7M | $-7M | -134.9% |
| Dec 2019 | $8M | -13.0% | $-4M | $-8M | -89.8% |
| Dec 2018 | $10M | — | $-8M | $-7M | -77.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-3M | $0M | $-3M | $-0.07 | — |
| Dec 2024 | $-3M | $0M | $-3M | $-0.06 | — |
| Dec 2023 | $-5M | — | — | — | — |
| Dec 2022 | $-6M | $0M | $-6M | — | — |
| Dec 2021 | $-4M | $0M | $-4M | $-0.10 | — |
| Dec 2020 | $-7M | $0M | $-7M | $-0.12 | — |
| Dec 2019 | $-2M | $0M | $-2M | $-0.16 | — |
| Dec 2018 | $-2M | $0M | $-2M | $-0.21 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M (-5.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 31, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jul 29, 20268-KCurrent reportOther events
- Jun 25, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Regulation FD disclosure
- Jun 22, 2026DEF 14AProxy statement
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportAuditor change
- May 6, 20268-KCurrent reportDirectors or officers changed
- May 5, 202610-K/AAnnual report (amended) · period to Dec 2025
- Apr 21, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Apr 2, 20268-KCurrent reportMaterial agreement
- Mar 31, 202610-KAnnual report · period to Dec 2025
Official filings of Milestone Scientific Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $9 M
- Operating income
- $-6 M
- Net income
- $-6 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $5 M
- Total equity
- $3 M
As of December-2025
Top 32 institutional investors in Milestone Scientific Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2,159,856 | +86,690 (+4.18%) | 2.43% | $1 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 654,454 | +10,843 (+1.68%) | 0.74% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 464,449 | 0 (0.00%) | 0.52% | $0 M | Nov 13, 2026 |
| 4 | State Street Corp | 264,885 | 0 (0.00%) | 0.30% | $0 M | Nov 12, 2026 |
| 5 | NFSG Corp | 221,000 | +80,000 (+56.74%) | 0.25% | $0 M | Oct 15, 2026 |
| 6 | Citadel Advisors LLC | 135,051 | New | 0.15% | $0 M | Nov 16, 2026 |
| 7 | Northern Trust Corp | 133,067 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 8 | LPL Financial LLC | 124,945 | 0 (0.00%) | 0.14% | $0 M | Nov 6, 2026 |
| 9 | Mariner, LLC | 121,750 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 10 | Carnegie Investment Counsel | 100,175 | 0 (0.00%) | 0.11% | $0 M | Oct 20, 2026 |
| 11 | Bridgeway Capital Management, LLC | 97,757 | -1,743 (-1.75%) | 0.11% | $0 M | Nov 16, 2026 |
| 12 | Empowered Funds, LLC | 97,757 | New | 0.11% | $0 M | Nov 13, 2026 |
| 13 | BlackRock, Inc. | 65,453 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 14 | XTX Topco Ltd | 54,339 | +19,496 (+55.95%) | 0.06% | $0 M | Nov 16, 2026 |
| 15 | HRT Financial LP | 51,753 | New | 0.06% | $0 M | Nov 13, 2026 |
| 16 | Commonwealth Equity Services, LLC | 44,782 | 0 (0.00%) | 0.05% | $0 M | Nov 2, 2026 |
| 17 | Sequoia Financial Advisors, LLC | 43,422 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 18 | Kestra Advisory Services, LLC | 41,100 | 0 (0.00%) | 0.05% | $0 M | Nov 2, 2026 |
| 19 | Susquehanna International Group, LLP | 25,685 | New | 0.03% | $0 M | Nov 16, 2026 |
| 20 | Cetera Investment Advisers | 18,975 | +1,825 (+10.64%) | 0.02% | $0 M | Nov 13, 2026 |
| 21 | HighTower Advisors, LLC | 15,666 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 22 | Radnor Capital Management, LLC | 15,000 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 23 | Vanguard Global Advisers, LLC | 14,867 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 24 | Daniel Investment Group, Inc. | 13,076 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 25 | Tower Research Capital LLC (TRC) | 10,050 | New | 0.01% | $0 M | Nov 16, 2026 |
Show all 32: investors 26 to 32
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Oppenheimer & Co Inc | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 26, 2026 |
| 27 | UBS Group AG | 4,986 | -3,604 (-41.96%) | 0.01% | $0 M | Nov 10, 2026 |
| 28 | Morgan Stanley | 1,953 | -1,058 (-35.14%) | 0.00% | $0 M | Nov 13, 2026 |
| 29 | Royal Bank Of Canada | 549 | New | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Jpmorgan Chase & Co | 220 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | FMR LLC | 140 | New | 0.00% | $0 M | Nov 10, 2026 |
| 32 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Milestone Scientific Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.45 M | $0 M | 1.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 611,482 | $0 M | 0.69% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 330,613 | $0 M | 0.37% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 101,876 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 99,500 | $0 M | 0.11% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 72,271 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,938 | $0 M | 0.01% | <0.01% | −2.7% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Milestone Scientific Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | S.r.l. Bp410% owner | Sell | -100,000 | $0.440 | $44 K | 8.90 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -80,000 | $0.430 | $34 K | 9.00 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -14,427 | $0.450 | $6 K | 9.08 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -40,000 | $0.440 | $18 K | 9.09 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -24,034 | $0.450 | $11 K | 9.13 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -30,000 | $0.540 | $16 K | 9.16 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -10,000 | $0.550 | $6 K | 9.18 M | Form 4 |
| filed | S.r.l. Bp410% owner | Sell | -10,158 | $0.550 | $6 K | 9.19 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Milestone Scientific Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 172 shares at $0.34
- : 373 shares at $0.41
- : 385 shares at $0.42
- : 1,176 shares at $0.42
- : 446 shares at $0.47
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Milestone Scientific Inc. scorecard#
Passes 4 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median11.0×Price to book 11.0× against Medical Instruments's median of 3.9×.
- ✗Price to sales below its peers' median3.3×Price to sales 3.3× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%-9.5%Free cash flow is -9.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✓Revenue grew in the newest year3.9%Revenue up 3.9% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years0.6%0.6% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median0.6%0.6% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year-0.07 vs -0.06Diluted EPS -0.07 in fiscal 2025 against -0.06 the year before (report's currency).
- ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$7 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-63.5%-63.5% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%-132.4%-132.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-63.5%-63.5% in fiscal 2025 against -100.2% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.81 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-21.02Z-score -21.02 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.9%Diluted shares up 2.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Milestone Scientific Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -63.6% | 7.2% | |
| Net margin | -63.8% | 3.8% | |
| Return on equity | -132.4% | 3.5% | |
| Revenue growth, 3 years a year | 0.6% | 5.0% | |
| Revenue growth | 3.9% | 8.9% | |
| Free cash flow margin | -32.8% | 6.3% |
2of 8on the Piotroski tests of financial strength
- Net loss of $6 million, the 12th loss-making year in a row.
- Free cash flow was negative: -$3 million.
Milestone Scientific Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 9.0+4.0%100% | 8.6−12.2%100% | 9.8+11.6%100% | 8.8−14.5%100% | 10+89.5%100% | 5.4−35.1%100% | 8.4−13.0%100% | 9.6−14.7%100% | 11+7.6%100% | 10—100% | |
| Cost of revenue | 2.6+16.9%28.6% | 2.2−27.7%25.4% | 3.0−22.3%30.9% | 3.9−2.2%44.3% | 4.0+120%38.7% | 1.8−31.6%33.4% | 2.7−48.8%31.7% | 5.2+20.4%53.9% | 4.3+3.3%38.2% | 4.2—39.8% | |
| Gross profit | 6.4−0.4%71.4% | 6.4−5.3%74.6% | 6.8+38.6%69.1% | 4.9−22.4%55.7% | 6.3+74.3%61.3% | 3.6−36.7%66.6% | 5.7+29.0%68.3% | 4.4−36.4%46.1% | 7.0+10.5%61.8% | 6.3—60.2% | |
| Research and development | 0.4−47.7%5.0% | 0.9+22.4%10.0% | 0.7−39.0%7.1% | 1.2+31.0%13.1% | 0.9+185%8.5% | 0.3+62.1%5.7% | 0.2−22.7%2.3% | 0.2−9.9%2.6% | 0.3−78.5%2.4% | 1.3—12.1% | |
| Selling, general and administrative | 12−5.8%129% | 12−6.4%142% | 13+5.0%134% | 13−1.8%142% | 13+19.4%124% | 11r11+12.0%196% | 9.5−10.5%114% | 11−10.8%111% | 12+3.3%106% | 12—110% | |
| Operating expenses | 12−8.2%135% | 13−5.1%153% | 14+1.2%141% | 14+0.3%156% | 14+23.6%133% | 11+14.0%204% | 9.7−21.8%116% | 12+1.9%129% | 12−4.8%108% | 13—122% | |
| Operating income | −5.7—−63.5% | −6.8—−78.3% | −7.1—−72.3% | −8.8—−100% | −7.4—−71.6% | −7.5—−137% | −4.0—−47.8% | −8.0—−83.1% | −5.2—−46.4% | −6.5—−62.1% | |
| Interest and finance income | — | — | — | — | — | — | — | 0.0−19.9%0.1% | 0.0+624%0.1% | 0.0—0.0% | |
| Net interest income | — | 0.1−52.0%0.7% | 0.1+130%1.3% | 0.1—0.6% | −0.0—−0.2% | −0.0r0.0−1272%−0.3% | 0.0−79.3%0.0% | 0.0—0.1% | — | — | |
| Share of profit of associates | — | — | — | 0−100%0.0% | 0.2+148%2.4% | 0.1+20.4%1.8% | 0.1−75.3%1.0% | 0.3—3.4% | −0.1—−1.1% | −0.8—−7.6% | |
| Other non-operating income (expense) | — | — | — | — | — | −0.0—−0.5% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.0% | −0.0—−0.0% | |
| Income before tax | −5.7—−63.8% | −4.7—−54.6% | −7.0—−71.0% | −8.8—−99.6% | −7.1—−69.1% | −7.5—−137% | −7.6—−91.3% | −8.0—−83.1% | −5.2—−46.4% | −6.5—−62.2% | |
| Income tax | — | — | 0—0.0% | 0−100%0.0% | 0.0−97.9%0.0% | 0.0−14.5%0.3% | 0.0−24.4%0.2% | 0.0+25.6%0.2% | 0.0—0.2% | −0.0—−0.2% | |
| Net income including minority interests | — | −4.7—−54.6% | −7.0—−71.0% | −8.8—−99.6% | −6.9—−66.7% | −7.4—−136% | −7.6—−90.5% | −7.7—−79.9% | −5.4—−47.6% | −7.3—−69.6% | |
| Minority interests' share of net income | — | 0—0.0% | −0.1—−0.5% | −0.1—−0.8% | −0.1—−0.6% | −0.1—−0.9% | −0.1—−0.7% | −0.3—−2.7% | −0.2—−1.6% | −1.3—−12.9% | |
| Net income attributable to shareholders | −5.7—−63.8% | −4.7—−54.6% | −6.9—−70.5% | −8.7—−98.9% | −6.8—−66.2% | −7.3—−135% | −7.5—−89.8% | −7.4—−77.2% | −5.2—−46.0% | −5.9—−56.7% | |
| Earnings per share, basic | -0.07—— | -0.06—— | -0.10—— | -0.12—— | -0.10—— | -0.12—— | -0.16—— | -0.21—— | -0.16—— | -0.22—— | |
| Earnings per share, diluted | -0.07—— | -0.06—— | — | — | -0.10—— | -0.12—— | -0.16—— | -0.21—— | -0.16—— | -0.22—— | |
| Shares, weighted average (basic) | 82+2.8%— | 80+9.6%— | 73+3.1%— | 71+2.6%— | 69+9.1%— | 63+37.9%— | 46+29.6%— | 35+7.9%— | 33+21.3%— | 27—— | |
| Shares, weighted average (diluted) | 82+2.8%— | 80—— | — | — | 69+9.1%— | 63+37.9%— | 46+29.6%— | 35+7.9%— | 33+21.3%— | 27—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.1r1.1−66.2%14.1% | 3.3+9.4%33.3% | 3.0−65.8%26.2% | 8.7−41.0%63.6% | 15+3.8%74.5% | 14+838%72.7% | 1.5−24.0%23.1% | 2.0r0.7−24.3%31.2% | 2.6−26.8%16.9% | 3.6—25.4% | |
| Short-term investments | — | 0−100%0.0% | 3.0−65.8%26.2% | 8.7−41.2%63.5% | 15r14+13.0%74.7% | 13+4238%66.9% | 0.3—4.6% | — | — | — | |
| Receivables | — | 0.5+52.0%4.9% | 0.3−54.9%2.7% | 0.7−26.5%5.1% | 0.9−12.7%4.8% | 1.1−36.8%5.5% | 1.7−13.5%26.1% | 2.0+28.8%30.9% | 1.5+91.4%9.8% | 0.8—5.7% | |
| Inventory | 3.8+1.8%48.4% | 3.7+40.7%37.9% | 2.6+47.2%23.2% | 1.8+16.3%13.1% | 1.5−36.3%7.8% | 2.4+49.3%12.4% | 1.6−15.6%24.7% | 1.9−43.2%30.0% | 3.4−26.6%21.6% | 4.6—32.5% | |
| Other current assets | 0.5−17.0%6.0% | 0.6+9.1%5.8% | 0.5+16.7%4.6% | 0.4+18.3%3.2% | 0.4−9.8%1.9% | 0.4−19.9%2.1% | 0.5+25.2%7.9% | 0.4−5.0%6.5% | 0.4+49.5%2.8% | 0.3—2.1% | |
| Current assets | 7.5−19.5%95.8% | 9.3−14.0%94.8% | 11−16.8%94.9% | 13−31.5%94.7% | 19+2.0%95.6% | 19+205%94.8% | 6.1r6.1+3.8%92.7% | 5.9−51.3%91.5% | 12−9.9%76.9% | 13r13—94.1% | |
| Property, plant and equipment | 0.0+48.5%0.2% | 0.0+28.9%0.1% | 0.0−44.8%0.1% | 0.0−23.5%0.1% | 0.0−22.8%0.1% | 0.0−31.7%0.2% | 0.0−45.5%0.7% | 0.1−41.8%1.3% | 0.1−10.9%0.9% | 0.2—1.1% | |
| Right-of-use (leased) assets | 0.2−41.7%1.9% | 0.3−27.4%2.6% | 0.4−19.9%3.1% | 0.4−15.4%3.2% | 0.5r0.6−17.1%2.6% | 0.6r0.6+3859%3.2% | 0.0r0.0—0.2% | — | — | — | |
| Other intangible assets | 0.1−46.7%1.0% | 0.1−16.9%1.5% | 0.2−21.6%1.6% | 0.2−17.9%1.7% | 0.3−15.7%1.4% | 0.3−13.9%1.7% | 0.4−12.2%5.8% | 0.4−84.4%6.8% | 2.8+322%17.9% | 0.7—4.7% | |
| Total assets | 7.8−20.3%100% | 9.8−13.8%100% | 11−17.0%100% | 14−30.8%100% | 20+1.2%100% | 20+199%100% | 6.6+2.4%100% | 6.4−59.0%100% | 16+10.2%100% | 14r14—100% | |
| Accounts payable | — | — | — | 1.1+41.3%8.0% | 0.8+61.6%3.9% | 0.5−65.0%2.5% | 1.4+30.2%21.0% | 1.1r1.2+8.3%16.5% | 1.0r1.0−27.1%6.3% | 1.3r2.6—9.5% | |
| Current liabilities | 3.9r4.1+5.1%50.4% | 3.7+21.7%38.2% | 3.1−6.8%27.1% | 3.3+6.5%24.1% | 3.1+7.6%15.6% | 2.9−41.6%14.7% | 4.9+1.1%75.2% | 4.9−27.6%76.1% | 6.7+19.2%43.0% | 5.6r5.0—39.8% | |
| Lease liabilities (non-current) | 0.0−78.7%0.5% | 0.2−41.3%1.7% | 0.3−26.8%2.5% | 0.4−19.2%2.8% | 0.5−14.5%2.4% | 0.6—2.9% | — | — | — | — | |
| Total liabilities | 4.8r5.0+21.0%61.5% | 4.0+18.0%40.5% | 3.4−9.1%29.5% | 3.7+2.8%27.0% | 3.6+3.7%18.1% | 3.5−29.7%17.7% | 4.9+1.1%75.2% | 4.9−40.1%76.1% | 8.1+44.0%52.0% | 5.6—39.8% | |
| Retained earnings | −134r−134—−1711% | −128—−1307% | −123—−1085% | −116—−850% | −108—−544% | −101—−515% | −94—−1426% | −86—−1344% | −79—−503% | −73—−517% | |
| Shareholders' equity | 3.0r2.8−48.4%38.5% | 5.8−27.2%59.5% | 8.0−21.6%70.5% | 10−37.5%74.6% | 16+1.0%82.6% | 16+855%82.8% | 1.7+10.2%25.9% | 1.5−78.7%24.1% | 7.2−14.8%46.3% | 8.5—59.9% | |
| Minority interests | — | — | 0—0.0% | −0.2—−1.6% | −0.2—−0.8% | −0.1—−0.5% | −0.1—−1.0% | −0.0−104%−0.2% | 0.3+611%1.6% | 0.0—0.3% | |
| Total equity | — | 5.8−27.2%59.5% | 8.0−19.9%70.5% | 10−38.3%73.0% | 16+0.7%81.9% | 16+889%82.3% | 1.6+6.6%24.8% | 1.5−79.6%23.9% | 7.5−12.1%48.0% | 8.5—60.2% | |
| Total liabilities and equity | 7.8−20.3%100% | 9.8−13.8%100% | 11−17.0%100% | 14−30.8%100% | 20+1.2%100% | 20+199%100% | 6.6+2.4%100% | 6.4−59.0%100% | 16+10.2%100% | 14r14—100% | |
| Shares outstanding | 80+3.1%— | 78+2.9%— | 76+9.5%— | 69+1.7%— | 68+6.2%— | 64+29.9%— | 49+46.0%— | 34+2.0%— | 33+9.0%— | 30—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.1+109%0.9% | 0.0−39.5%0.4% | 0.1−2.9%0.6% | 0.1−13.7%0.7% | 0.1−23.0%0.7% | 0.1−4.5%1.8% | 0.1−88.6%1.2% | 0.9+53.8%9.2% | 0.6—5.1% | — | |
| Share-based compensation | 1.0−29.2%10.6% | 1.3−8.3%15.6% | 1.5−2.1%14.9% | 1.5+89.6%17.0% | 0.8+43.7%7.7% | 0.6+199%10.1% | 0.2−55.0%2.2% | 0.4−37.2%4.3% | 0.7−64.8%5.8% | 1.9—17.7% | |
| Cash from operating activities | −2.9—−32.5% | −2.9—−33.8% | −5.3—−54.2% | −6.0—−68.5% | −4.0r−4.0—−39.1% | −7.0—−128% | −1.8—−21.2% | −1.6—−16.9% | −1.2—−10.9% | −5.4—−51.5% | |
| Capital expenditure | −0.0—−0.2% | −0.0—−0.1% | — | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.4% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.1% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | −0.0—−0.4% | −0.0—−0.1% | |
| Cash from investing activities | −0.0−101%−0.2% | 3.0—34.4% | −3.0—−30.2% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.4% | −0.0—−0.1% | −0.0—−0.2% | −0.2−2527%−1.8% | 0.0—0.1% | |
| Debt issued | 0.8—8.9% | — | — | — | — | — | — | — | — | — | |
| Shares issued | — | — | 2.6—26.2% | 0—0.0% | 0−100%0.0% | 18+814%332% | 2.0—23.6% | — | 0.2−94.1%1.3% | 2.6—24.5% | |
| Cash from financing activities | 0.8+236%8.8% | 0.2−90.9%2.7% | 2.6—26.1% | −0.0−100%−0.1% | 4.6r4.6−76.7%44.5% | 20+669%363% | 2.6—30.6% | −0.3−154%−2.6% | 0.5−90.3%4.1% | 4.8—45.8% | |
| Change in cash | −2.1−865%−23.9% | 0.3—3.2% | −5.7—−58.4% | −6.0−1219%−68.7% | 0.5−95.7%5.2% | 13+1544%234% | 0.8—9.2% | −1.9—−19.7% | −1.0—−8.6% | −0.6—−5.6% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 9.3+3.9%100% | 2.2−5.9%100% | 2.8+22.3%100% | 2.2−3.2%100% | 2.1*+2.2%100% | 2.4−6.1%100% | 2.3+25.3%100% | 2.2−0.7%100% | 2.0*−10.9%100% | 2.5—100% | 1.9—100% | 2.2—100% | 2.3*—100% | |
| Cost of revenue | 2.7+7.4%29.1% | 0.6−14.6%27.7% | 0.9+31.9%32.8% | 0.6+2.2%27.7% | 0.6*+10.7%27.0% | 0.7+6.1%30.5% | 0.7+59.5%30.4% | 0.6+2.1%26.2% | 0.5*−33.0%25.0% | 0.7—27.0% | 0.4—23.9% | 0.6—25.5% | 0.8*—33.2% | |
| Gross profit | 6.6+2.6%70.9% | 1.6−2.2%72.3% | 1.9+18.1%67.2% | 1.6−5.1%72.3% | 1.5*−0.6%73.0% | 1.6−10.6%69.5% | 1.6+14.6%69.6% | 1.6−1.7%73.8% | 1.5*+0.0%75.0% | 1.8—73.0% | 1.4—76.1% | 1.7—74.5% | 1.5*—66.8% | |
| Research and development | — | 0.0−35.8%0.5% | 0.0−87.2%0.2% | — | 0.0*−94.3%0.6% | 0.0−93.0%0.7% | 0.1−83.6%2.2% | 0.4+292%16.5% | 0.2*+23.0%10.8% | 0.2—9.2% | 0.3—17.0% | 0.1—4.2% | 0.2*—7.8% | |
| Selling, general and administrative | 10−17.5%110% | 2.3−15.2%105% | 2.9−2.8%104% | 2.4−27.1%110% | 2.5*−23.4%124% | 2.7−10.6%116% | 3.0+5.7%130% | 3.3+7.3%146% | 3.3*+0.8%165% | 3.1—122% | 2.9—155% | 3.0—135% | 3.3*—146% | |
| Operating expenses | 10−21.3%111% | 2.4−15.3%106% | 3.0−4.2%105% | 2.4−34.4%111% | 2.6*−27.4%125% | 2.8−16.0%118% | 3.1−2.8%134% | 3.6+16.0%163% | 3.6*+1.8%176% | 3.3—131% | 3.2—172% | 3.1—140% | 3.5*—154% | |
| Operating income | −3.7—−40.0% | −0.7—−33.6% | −1.1—−37.4% | −0.8—−38.3% | −1.1*—−52.5% | −1.1—−48.1% | −1.5—−63.9% | −2.0—−89.5% | −2.0*—−101% | −1.5—−58.4% | −1.8—−96.0% | −1.5—−65.1% | −2.0*—−87.6% | |
| Net interest income | — | — | — | — | — | — | 0.0−92.7%0.1% | 0.0−86.7%0.1% | 0.0*−70.5%0.3% | 0.0—0.3% | 0.0—1.1% | 0.0r−0.0—1.1% | 0.0*—1.0% | |
| Income before tax | −3.7—−40.3% | −0.7—−33.7% | −1.1—−37.3% | −0.8—−38.8% | −1.1*—−53.0% | −1.2—−48.9% | −1.5−763%−63.8% | −2.0—−89.3% | −2.0*—−101% | −1.5—−58.1% | 0.2—12.1% | −1.4—−64.1% | −2.0*—−86.6% | |
| Income tax | — | — | — | — | — | — | 0—0.0% | — | — | — | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Net income including minority interests | — | — | — | — | — | — | −1.5−763%−63.8% | −2.0—−89.3% | −2.0*—−101% | −1.5—−58.1% | 0.2—12.1% | −1.4—−64.1% | −2.0*—−86.6% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.0*—−0.8% | |
| Net income attributable to shareholders | −3.6—−38.3% | −0.7—−33.7% | −1.0r−1.1—−33.8% | −0.8r−0.8—−35.1% | −1.1*—−53.0% | −1.2—−48.9% | −1.5−763%−63.8% | −2.0—−89.3% | −2.0*—−101% | −1.5—−58.1% | 0.2—12.1% | −1.4—−64.1% | −1.9*—−85.8% | |
| Earnings per share, basic | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | -0.02—— | -0.02—— | — | -0.02—— | 0.00—— | -0.02—— | — | |
| Earnings per share, diluted | — | -0.01—— | -0.01—— | -0.01—— | — | -0.01—— | -0.02—— | -0.02—— | — | -0.02—— | — | — | — | |
| Shares, weighted average (basic) | 94+14.1%— | 94+14.1%— | 93+13.5%— | 85+3.9%— | — | 82+2.9%— | 82+2.6%— | 82+2.7%— | — | 80—— | 80—— | 80—— | — | |
| Shares, weighted average (diluted) | 94+14.1%— | 94+14.1%— | 93+13.5%— | 85+3.9%— | — | 82+2.9%— | 82+2.6%— | 82—— | — | 80—— | 80—— | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.3—18.9% | 1.3−2.2%18.9% | 2.1+62.2%24.8% | 1.2−46.6%15.1% | 1.1r1.1−66.2%14.1% | 1.3−71.8%15.9% | 1.3−77.8%15.8% | 2.2−43.9%24.7% | 3.3+9.4%33.3% | 4.8—42.7% | 5.8—47.9% | 4.0—35.3% | 3.0—26.2% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 1.0—8.8% | 3.0—26.2% | |
| Receivables | — | — | — | — | — | — | — | — | 0.5+52.0%4.9% | 0.6—4.9% | 0.4—3.2% | 0.7—5.8% | 0.3—2.7% | |
| Inventory | 2.7—39.4% | 2.7−33.7%39.4% | 3.1−20.8%37.0% | 3.5−16.1%43.8% | 3.8+1.8%48.4% | 4.1+11.2%48.6% | 3.9+17.1%48.4% | 4.2+45.4%45.8% | 3.7+40.7%37.9% | 3.7—33.2% | 3.3—27.7% | 2.9—25.2% | 2.6—23.2% | |
| Other current assets | 0.3—4.0% | 0.3−44.9%4.0% | 0.6−0.6%7.6% | 0.7−9.8%8.5% | 0.5−17.0%6.0% | 0.5−21.6%6.0% | 0.6−17.7%7.9% | 0.8−13.1%8.3% | 0.6+9.1%5.8% | 0.6—5.8% | 0.8—6.5% | 0.9—7.6% | 0.5—4.6% | |
| Current assets | 6.8—97.4% | 6.8−16.6%97.4% | 8.1+6.4%97.2% | 7.4−14.8%92.3% | 7.5−19.5%95.8% | 8.1−24.2%95.6% | 7.6−33.6%94.8% | 8.6−20.2%94.9% | 9.3−14.0%94.8% | 11—95.7% | 11—95.7% | 11—95.3% | 11—94.9% | |
| Property, plant and equipment | 0.0—0.3% | 0.0+3.0%0.3% | 0.0+37.2%0.2% | 0.0+50.9%0.2% | 0.0+48.5%0.2% | 0.0+62.0%0.2% | 0.0+12.9%0.2% | 0.0+52.6%0.1% | 0.0+28.9%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0.1—0.9% | 0.1−65.0%0.9% | 0.1−56.9%1.1% | 0.1−47.5%1.5% | 0.2−41.7%1.9% | 0.2−37.0%2.1% | 0.2−30.3%2.7% | 0.2−29.9%2.6% | 0.3−27.4%2.6% | 0.3—2.5% | 0.3—2.6% | 0.3—2.9% | 0.4—3.1% | |
| Other intangible assets | 0.0—0.4% | 0.0−71.1%0.4% | 0.0−60.5%0.5% | 0.1−52.7%0.8% | 0.1−46.7%1.0% | 0.1−38.1%1.1% | 0.1−30.0%1.4% | 0.1−22.5%1.4% | 0.1−16.9%1.5% | 0.2—1.4% | 0.2—1.4% | 0.2—1.5% | 0.2—1.6% | |
| Total assets | 6.9—100% | 6.9−18.2%100% | 8.3+3.7%100% | 8.0−12.4%100% | 7.8−20.3%100% | 8.5−24.1%100% | 8.1−32.9%100% | 9.1−19.9%100% | 9.8−13.8%100% | 11—100% | 12—100% | 11—100% | 11—100% | |
| Current liabilities | 3.3—47.2% | 3.3−34.8%47.2% | 4.4+16.7%52.7% | 4.9+9.3%61.0% | 3.9r4.1+5.1%50.4% | 5.0+33.9%59.3% | 3.8−1.5%46.8% | 4.4+22.2%48.9% | 3.7+21.7%38.2% | 3.8—33.6% | 3.8—31.9% | 3.6—32.0% | 3.1—27.1% | |
| Lease liabilities (non-current) | — | — | — | — | 0.0−78.7%0.5% | 0.1−64.8%0.8% | 0.1−54.7%1.3% | 0.1−47.2%1.5% | 0.2−41.3%1.7% | 0.2—1.8% | 0.2—1.9% | 0.3—2.2% | 0.3—2.5% | |
| Total liabilities | 3.3—47.3% | 3.3−44.6%47.3% | 4.9+3.5%58.4% | 5.7+22.8%71.3% | 4.8r5.0+21.0%61.5% | 5.9+50.2%70.0% | 4.7+16.3%58.5% | 4.6+18.9%50.9% | 4.0+18.0%40.5% | 4.0—35.4% | 4.1—33.7% | 3.9—34.3% | 3.4—29.5% | |
| Retained earnings | −136—−1960% | −136—−1960% | −136—−1625% | −135—−1691% | −134r−134—−1711% | −133—−1564% | −132—−1634% | −130—−1431% | −128—−1307% | −126—−1128% | −125—−1038% | −125—−1099% | −123—−1085% | |
| Shareholders' equity | 3.7—52.7% | 3.7+43.4%52.7% | 3.8r3.5+15.1%46.1% | 2.6r2.3−42.6%32.2% | 3.0r2.8−48.4%38.5% | 2.5−64.7%30.0% | 3.3−58.0%41.5% | 4.5−40.2%49.1% | 5.8−27.2%59.5% | 7.2—64.6% | 8.0—66.3% | 7.5—65.7% | 8.0—70.5% | |
| Minority interests | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total equity | — | — | — | — | — | — | 3.3−58.0%41.5% | 4.5−40.2%49.1% | 5.8−27.2%59.5% | 7.2—64.6% | 8.0—66.3% | 7.5—65.7% | 8.0—70.5% | |
| Total liabilities and equity | 6.9—100% | 6.9−18.2%100% | 8.3+3.7%100% | 8.0−12.4%100% | 7.8−20.3%100% | 8.5−24.1%100% | 8.1−32.9%100% | 9.1−19.9%100% | 9.8−13.8%100% | 11—100% | 12—100% | 11—100% | 11—100% | |
| Shares outstanding | 91—— | 91+15.3%— | 89+13.0%— | 80+2.9%— | 80+3.1%— | 79+1.1%— | 79+1.8%— | 78+2.1%— | 78+2.9%— | 78—— | 77—— | 77—— | 76—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+15.6%0.8% | 0.0−0.0%0.9% | 0.0+0.5%0.7% | 0.0+0.1%0.9% | 0.0*+120%0.9% | 0.0+134%0.9% | 0.0+130%0.8% | 0.0+66.4%0.9% | 0.0*−28.1%0.4% | 0.0—0.3% | 0.0—0.5% | 0.0—0.5% | 0.0*—0.5% | |
| Share-based compensation | 0.8−35.9%8.2% | 0.1*−72.6%4.5% | 0.3*+93.9%10.9% | 0.3−22.4%11.9% | 0.1*−70.8%4.8% | 0.4*−25.0%15.4% | 0.2−23.1%6.9% | 0.3+5.5%14.8% | 0.3*−4.0%16.9% | 0.5*—19.3% | 0.2—11.2% | 0.3—13.9% | 0.4*—15.7% | |
| Cash from operating activities | −1.5—−15.8% | −0.7*−1013%−33.6% | −0.6*—−20.6% | 0.1—4.0% | −0.2*—−11.0% | 0.1*—3.5% | −1.8*−325%−75.9% | −1.0—−45.2% | −1.5*—−75.1% | −1.0*—−38.7% | 0.8*—42.3% | −1.2—−54.2% | −1.2*—−55.1% | |
| Capital expenditure | −0.0—−0.1% | −0.0*—−0.1% | −0.0*—−0.1% | −0.0—−0.1% | −0.0*—−0.2% | −0.0*—−0.3% | −0.0*—−0.2% | −0.0—−0.1% | −0.0*—−0.2% | — | — | — | — | |
| Cash from investing activities | −0.0—−0.1% | −0.0*—−0.1% | −0.0*—−0.1% | −0.0—−0.1% | −0.0*—−0.2% | −0.0*—−0.3% | −0.0*−100%−0.2% | −0.0−100%−0.1% | −0.0*—−0.2% | 0*—0.0% | 1.0*—52.1% | 2.0—89.1% | −0.5*—−22.8% | |
| Debt issued | — | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | — | |
| Cash from financing activities | 1.5+84.4%15.6% | −0.0*—−0.2% | 1.5*+83.5%51.4% | −0.0—−0.2% | −0.0*—−0.2% | −0.0*—−0.2% | 0.8*—34.3% | −0.0−101%−0.1% | −0.0*−100%−0.1% | −0.0*—−0.1% | −0.0*—−0.1% | 0.2—10.7% | 2.6*—114% | |
| Change in cash | −0.0—−0.3% | −0.8*−1158%−33.8% | 0.9*—30.7% | 0.1—3.8% | −0.2*—−11.3% | 0.1*—3.0% | −1.0*−156%−41.8% | −1.0−198%−45.3% | −1.5*−288%−75.4% | −1.0*—−38.8% | 1.7*—94.2% | 1.0—45.7% | 0.8*—35.7% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Milestone Scientific Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Handpieces$7 M80%+2.4%
- Instruments$2 M20%+12%
- Other$0 M0.8%-22%
Business segments
- Dental$9 M98%+3.0%
- Dental$9 M98%+3.0%
- Medical$0 M2.0%+80%
- Medical$0 M2.0%+80%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Milestone Scientific Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Milestone Scientific Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $795 K | $77 K | $497 K | $29 |
| 2024Chief executive | $881 K | $881 K | — | $137 |
| 2023Chief executive | $680 K | $680 K | — | $150 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Milestone Scientific Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 1 · Auditor changed 2 · Directors and officers 8 · Material agreement 7 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3
| Filed | What happened | Filing |
|---|---|---|
| Directors and officersShareholder vote | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Product recalls by Milestone Scientific Inc.#
1 recalls since 2015, 165,850 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Milestone Wand STA Handpiece for the delivery of local anesthesia to dental tissue. Model Number STA-5050-305. The Wand STA handpiece is a single use syringe used in conjunction with the CompuDent STA computer controlled dental injection system.Wand Handpiece was mislabeled as STA handpiece. The Wand handpiece cannot be installed in the STA instrument.Medical devicesClass III | 165,850 | Z-1952-2015 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Milestone Scientific Inc. compares in Medical Instruments
- Market cap$31 M · higher than 4% of 116
- Revenue$9 M · higher than 7% of 120
- Net margin-44.1% · higher than 5% of 114
- Revenue growth3.9% · higher than 27% of 49
- Price / sales3.3× · lower than 46% of 85
- Price / book11.0× · lower than 7% of 84
- FCF yield-9.5% · higher than 21% of 39
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Milestone Scientific Inc.🇺🇸 | $31 M | — | -44.1% | +3.9% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 14, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 21, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Milestone Scientific Inc.? Verify and update this profile — free
Show Milestone Scientific Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.